Review demonstrates the rising burden and therapeutic landscape of steatotic liver disease in patients with cardiometabolic disorders, highlighting integration of metabolic therapies.
Key Points
To synthesize current evidence regarding the epidemiology, pathophysiology, and clinical management of metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction–associated steatohepatitis (MASH).
Narrative synthesis of recent literature on the biological mechanisms, risk factors, and systemic consequences of MASLD and MASH.
Evaluation of treatment strategies combining established cardiometabolic interventions with emerging pharmacotherapies.
MASLD and MASH are intimately linked to insulin resistance and cardiometabolic disorders, forming a critical component of systemic metabolic syndrome.
Optimal management requires integrating standard cardiometabolic care with newly developed disease-specific treatments to mitigate progressive liver injury and associated complications.